acp-204
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Nov 14, 2023 (NCT06159673)
Timeline
Indications
Studied for
Mechanism of action
- Serotonin 2a (5-HT2a) receptorINVERSE AGONIST
HTR2A inverse agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07095465 | Phase 3 | Aug 31, 2025 | Acadia Pharmaceuticals |
| NCT07029581 | Phase 2 | Aug 6, 2025 | Acadia Pharmaceuticals |
| NCT06194799 | Phase 3 | Apr 23, 2024 | Acadia Pharmaceuticals |
| NCT06159673 | Phase 2/Phase 3 (Phase 3) | Nov 14, 2023 | Acadia Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acadia Pharmaceuticals | For profit | 4 | 4 | 2 | 2023 |
1 organizations
Page 1 / 1